Patent 10166200 was granted and assigned to NuvOx Pharma on January, 2019 by the United States Patent and Trademark Office.
An oxygen therapeutic composition, which includes a perfluorocarbon material having a boiling point of about 4 degrees Celsius to about 60 degrees Celsius, a lipid; a viscosity modifier; a buffer.